Ixekizumab Side Effects

For the Consumer

Applies to ixekizumab: subcutaneous solution

In addition to its needed effects, some unwanted effects may be caused by ixekizumab. In the event that any of these side effects do occur, they may require medical attention.

Major Side Effects

You should check with your doctor immediately if any of these side effects occur when taking ixekizumab:

• Body aches or pain
• burning, dry, or itching eyes
• cough or hoarseness
• difficulty with breathing
• discharge or excessive tearing
• ear congestion
• fever or chills
• headache
• itching in the genital or other skin areas
• loss of voice
• lower back or side pain
• nasal congestion
• painful or difficult urination
• redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid
• runny nose
• sneezing
• sore mouth or tongue
• sore throat
• unusual tiredness or weakness
• white patches in the mouth or on the tongue

• Hives or welts, Itching, or skin rash
• large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
• rectal bleeding
• redness of the skin
• severe diarrhea
• severe stomach pain

Minor Side Effects

Some of the side effects that can occur with ixekizumab may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

• Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site

• Nausea

For Healthcare Professionals

Applies to ixekizumab: subcutaneous solution

Dermatologic

Common (1% to 10%): Urticaria
Uncommon (0.1% to 1%): Angioedema^[Ref]

Gastrointestinal

Common (1% to 10%): Nausea
Uncommon (0.1% to 1%): Oral candidiasis, inflammatory bowel disease^[Ref]

Hematologic

Very common (10% or more): Neutropenia (11%)
Common (1% to 10%): Thrombocytopenia^[Ref]

Immunologic

Very common (10% or more): Infections (26%), immunogenicity (22%)
Common (1% to 10%): Tinea infections, influenza
Uncommon (0.1% to 1%): Serious infections^[Ref]

Local

Very common (10% or more): Injection site reactions (17%), erythema, pain^[Ref]

Ocular

Common (1% to 10%): Conjunctivitis^[Ref]

Respiratory

Very common (10% or more): Upper respiratory tract infections (including nasopharyngitis and rhinovirus infection) (14%)
Uncommon (0.1% to 1%): Rhinitis^[Ref]

Not all side effects for ixekizumab may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.